The Australian government cancelled further trials and production of the vaccine after trials showed it could interfere with HIV diagnosis.
The University of Queensland commenced a Phase 1 trial of their COVID-19 vaccine candidate – v451 – in July 2020 in healthy volunteers. CSL was expected to conduct Phase 2/3 clinical trial and large-scale manufacture of the vaccine, upon completion of successful trials.
A press release issued by the University of Queensland stated that significant changes would need to be made to well-established HIV testing procedures in the healthcare setting to accommodate the rollout of this vaccine and hence the Australian government and CSL have agreed to halt the trials.
CSL, which had a contract to produce 51 million doses of the UQ vaccine, will instead produce an extra 20 million doses of the Oxford vaccine being developed with Britain’s AstraZeneca, the report said.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.